

Clinical Study

Annular closure in lumbar microdiscectomy for prevention of reherniation: a randomized clinical trial

Claudius Thomé, MD^{a,*}, Peter Douglas Klassen, MD^b, Gerrit Joan Bouma, MD^c, Adisa Kuršumović, MD^d, Javier Fandino, MD^e, Martin Barth, MD^f, Mark Arts, MD^g, Wimar van den Brink, MD^h, Richard Bostelmann, MDⁱ, Aldemar Hegewald, MD^j, Volkmar Heidecke, MD^k, Peter Vajkoczy, MD^l, Susanne Fröhlich, MD^m, Jasper Wolfs, MDⁿ, Richard Assaker, MD^o, Erik Van de Kelft, MD^p, Hans-Peter Köhler, MD^q, Senol Jadik, MD^r, Sandro Eustacchio, MD^s, Robert Hes, MD^t, Frederic Martens, MD^u on behalf of the Annular Closure RCT Study Group

^aDepartment of Neurosurgery, Medical University Innsbruck, Anichstrasse 35, A-6020, Innsbruck, Austria

^bDepartment of Neurosurgery, St. Bonifatius Hospital, Wilhelmstrasse 13, 49808, Lingen, Germany

^cDepartment of Neurosurgery, OLVG-West and Academic Medical Center, Jan Tooropstraat 164, 1006 AE, Amsterdam, The Netherlands

^dDepartment of Neurosurgery, Donauislar Klinikum Deggendorf, Perlasbergerstrasse 41, 94469, Deggendorf, Germany

^eDepartment of Neurosurgery, Kantonsspital Aarau, Tellstrasse 25, CH-5001, Aarau, Switzerland

^fDepartment of Neurosurgery, University Hospital Bochum, In der Schornau 23-25, D-44892, Bochum, Germany

^gDepartment of Neurosurgery, MCH Antoniushove, Albinusdreef 2, 2333 ZA Leiden, The Hague, The Netherlands

^hNeurochirurgisch Centrum Zwolle, Isala Ziekenhuis, Location Sophia P2.25, Dr van Heesweg 2, 8025 AB, Zwolle, The Netherlands

ⁱDepartment of Neurosurgery, University Hospital Düsseldorf, Moorenstrasse 5, House 13.71, D-40225, Düsseldorf, Germany

^jDepartment of Neurosurgery, Universitätsmedizin Mannheim, Theodore-Kutzer-Ufer 1-3, 68167, Mannheim, Germany

^kDepartment of Neurosurgery, Klinikum Augsburg, Stegelinstrasse 2, 86156, Augsburg, Germany

^lDepartment of Neurosurgery, Charité Universitätsmedizin, Augustenburger Platz 1, 13353, Berlin, Germany

^mDepartment of Orthopedics, Universität Rostock, Doberaner Str. 142, 18055, Rostock, Germany

ⁿDepartment of Neurosurgery, MCH Westenide, Albinusdreef 2, 2333 ZA Leiden, The Hague, The Netherlands

^oDepartment of Neurosurgery, Centre Hospitalier Régional Universitaire de Lille, 2 Avenue Oscar Lambret, 59000, Lille, France

^pDepartment of Neurosurgery, AZ Nikolaas, Moerlandstraat 1, B-9100, Sint-Niklaas, Belgium

^qDepartment of Neurosurgery, Asklepios Westklinikum Hamburg, Suurheid 20, D-22559, Hamburg, Germany

^rDepartment of Neurosurgery, University Hospital Kiel, University Medical Center Schleswig-Holstein, Arnold-Heller-Str. 3, Haus 41, 24105, Kiel, Germany

^sDepartment of Neurosurgery, LKH University Klinikum Graz, Auenbruggerplatz 1, 8036, Graz, Austria

^tDepartment of Neurosurgery, AZ Klina, Augustijnslei 100, 2930, Brasschaat, Belgium

^uDepartment of Neurosurgery, OLV Ziekenhuis, Moorselbaan 164, 9300, Aalst, Belgium

Received 9 December 2017; revised 25 April 2018; accepted 1 May 2018

Abstract

BACKGROUND CONTEXT: Patients with large annular defects after lumbar discectomy for disc herniation are at high risk of symptomatic recurrence and reoperation.

PURPOSE: The present study aimed to determine whether a bone-anchored annular closure device, in addition to lumbar microdiscectomy, resulted in lower reherniation and reoperation rates plus increased overall success compared with lumbar microdiscectomy alone.

DESIGN: This is a multicenter, randomized superiority study.

PATIENT SAMPLE: Patients with symptoms of lumbar disc herniation for at least 6 weeks with a large annular defect (6–10 mm width) after lumbar microdiscectomy were included in the study.

OUTCOME MEASURES: The co-primary end points determined a priori were recurrent herniation and a composite end point consisting of patient-reported, radiographic, and clinical outcomes. Study success required superiority of annular closure on both end points at 2-year follow-up.

METHODS: Patients received lumbar microdiscectomy with additional bone-anchored annular closure device (n=276 participants) or lumbar microdiscectomy only (control; n=278 participants). This research was supported by Intrinsic Therapeutics. Two authors received study-specific support more

than \$10,000 per year, 8 authors received study-specific support less than \$10,000 per year, and 11 authors received no study-specific support.

RESULTS: Among 554 randomized participants, 550 (annular closure device: n=272; control: n=278) were included in the modified intent-to-treat efficacy analysis and 550 (annular closure device: n=267; control: n=283) were included in the as-treated safety analysis. Both co-primary end points of the study were met, with recurrent herniation (50% vs. 70%, $P<.001$) and composite end point success (27% vs. 18%, $P=.02$) favoring annular closure device. The frequency of symptomatic reherniation was lower with annular closure device (12% vs. 25%, $P<.001$). There were 29 reoperations in 24 patients in the annular closure device group and 61 reoperations in 45 control patients. The frequency of reoperations to address recurrent herniation was 5% with annular closure device and 13% in controls ($P=.001$). End plate changes were more prevalent in the annular closure device group (84% vs. 30%, $P<.001$). Scores for back pain, leg pain, Oswestry Disability Index, and health-related quality of life at regular visits were comparable between groups over 2-year follow-up.

CONCLUSIONS: In patients at high risk of herniation recurrence after lumbar microdiscectomy, annular closure with a bone-anchored implant lowers the risk of symptomatic recurrence and reoperation. Additional study to determine outcomes beyond 2 years with a bone-anchored annular closure device is warranted. © 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Keywords: Annular closure; Disc herniation; Lumbar discectomy; Randomized controlled trial; Recurrent herniation; Sciatica

FDA device/drug status: Investigational.

Author disclosures: **CT:** Grant: Intrinsic Therapeutics (F, Paid directly to institution/employer); Consulting fee or honorarium: Intrinsic Therapeutics (D); Support for travel to meetings for the study or other purposes: Intrinsic Therapeutics (C), pertaining to the submitted work; Consulting: DePuy Synthes (C), SIGNUS Medzintechnik GmbH (D); Speaking and/or Teaching Arrangements: Brainlab (B), DePuy Synthes (C), Edge Therapeutics (B), Icotec (B), Medtronic (B), SIGNUS Medzintechnik GmbH (C); Grants: Brainlab (B, Paid directly to institution/employer), SIGNUS Medzintechnik GmbH (C, Paid directly to institution/employer), TETEC AG (E); Fellowship Support: Medtronic (D, Paid directly to institution/employer), DePuy Synthes (B, Paid directly to institution/employer), outside the submitted work. **PKD:** Consulting fee or honorarium: Intrinsic Therapeutics (D per annum, Paid directly to institution/employer); Support for travel to meetings for the study or other purposes: Intrinsic Therapeutics (C per annum); **GJB:** Grant: Intrinsic Therapeutics (F, Paid directly to institution/employer); Consulting fee or honorarium: Intrinsic Therapeutics (C); Support for travel to meetings for the study or other purposes: Intrinsic Therapeutics (B). **AK:** Grant: Intrinsic Therapeutics (F, Paid directly to institution/employer). Consulting fee or honorarium: Intrinsic Therapeutics (F); Support for travel to meetings for the study or other purposes: Intrinsic Therapeutics (B); Other: Intrinsic Therapeutics (C, Paid directly to institution/employer), pertaining to the submitted work; Consulting: Intrinsic Therapeutics (B); Trips/Travel: Intrinsic Therapeutics (B); Endowments: Intrinsic Therapeutics (B, Paid directly to institution/employer), outside the submitted work. **JF:** Nothing to disclose. **MB:** Nothing to disclose. **MA:** Consulting fee or honorarium: Intrinsic Therapeutics (A); Support for travel to meeting for the study or other purposes: Intrinsic Therapeutics (A), pertaining to the submitted work; Royalties: EIT (D); Consulting: EIT, Silony, Zimmer-Biomet, Amedica (A, Paid directly to institution/employer); Research Support (Investigator Salary, Staff/Materials): Zimmer-Biomet, EIT, Amedica (G [MISOS trial by Zimmer-Biomet], F [EFFECT trial by EIT], F [CASCADE trial by Amedica], Paid directly to institution/employer), outside the submitted work. **WvdB:** Reimbursement institution for patient follow-ups, radiology and data entry (B per patient, Paid directly to institution/employer). **RB:** Support for travel to meeting for the study or other purposes: Support for study coordinator meetings during the study period; Other: Fees from Intrinsic Therapeutics during the conduct of the study (D, Paid directly to institution/employer), pertaining

to the submitted work. **AH:** Universitätsmedizin Mannheim (E, Paid directly to institution/employer); Consulting fee of honorarium: Aldemar A. Hegewald (B); Support for travel to meetings for the study or other purposes: Aldemar A. Hegewald (B), pertaining to the submitted work. **VH:** Nothing to disclose. **PV:** Nothing to disclose. **SF:** Nothing to disclose. **JW:** Grant: Intrinsic Therapeutics (participation in the Barricaid trial); Consulting fee or honorarium: Intrinsic Therapeutics (participation in study, patient enrollment, follow-up; Support for travel to meetings for the study or other purposes: Intrinsic Therapeutics (Flights, hotel costs), pertaining to the submitted work; Speaking and/or Teaching Arrangements: Zimmer Biomet; Research Support (Investigator Salary, Staff/Materials): Zimmer Biomet EIT (MISOS trial, Effect trial), Royalties: EIT GmbH (D, Cages cervical, lumbar); Consulting: Safe orthopaedics, Silony, Zimmer Biomet, EIT (D, Consulting, medical advisory board, training and education), outside the submitted work. **RA:** Consulting fee or honorarium: Intrinsic Therapeutics (B); Support for travel to meetings for the study or other purposes: Intrinsic Therapeutics (A), pertaining to the submitted work; Royalties: Medtronic (F); Speaking and/or Teaching Arrangements: Medtronic (C), DePuy Synthes (B); Trips/Travel: DePuy Synthes (B), Medtronic (B); Scientific Advisory Board/Other Office (B), outside the submitted work. **EVdK:** Nothing to disclose. **HPK:** Nothing to disclose. **SJ:** Consulting fee or honorarium: Intrinsic Therapeutics (B); Support for travel to meetings for the study or other purposes: Intrinsic Therapeutics (A), pertaining to the submitted work. **SE:** Nothing to disclose. **RH:** Royalties: Globus Medical (B); Stock Ownership: Premia Spine (<10% of the company); Consulting: RTI Surgical (A); Speaking and/or Teaching Arrangements: RTI Surgical (A), outside the submitted work. **FM:** Nothing to disclose.

The disclosure key can be found on the Table of Contents and at www.TheSpineJournalOnline.com.

This research was supported by Intrinsic Therapeutics.

Intrinsic Therapeutics participated in the design and conduct of the study, management of the data, review of the manuscript, and the decision to submit the manuscript for publication but did not have the ability to veto submission.

* Corresponding author. Department of Neurosurgery, Medical University Innsbruck, Anichstraße 35 A-6020 Innsbruck, Innsbruck, Austria. Tel.: +43-512-504-27452.

E-mail address: claudius.thome@tirol-kliniken.at (C. Thomé)

Introduction

Sciatica is characterized by radiating buttock and leg pain in a lumbar nerve root distribution, which may be accompanied by sensory and motor deficits. The annual incidence of an episode of sciatica in the general population ranges from 1% to 5% [1]. The most common cause of sciatica is intervertebral disc herniation. Initial treatment of sciatica is conservative given the favorable natural history in most patients. In approximately 20% of patients, symptoms may persist despite conservative management [2,3]. These patients may continue conservative treatment or undergo surgical removal of herniated disc material, with surgery resulting in faster symptom relief [4]. However, recurrent symptomatic disc herniation occurs in 7%–18% of patients within 2 years after surgery [5–7]. Recurrent symptomatic herniation is associated with poor clinical outcome and requires a technically demanding, expensive reoperation in most cases [6,8]. With almost half a million discectomies performed in the United States per year [9], this poses a significant problem not only for the affected individuals but also for society overall.

As the annulus fibrosus has limited healing capacity, a large annular defect after microdiscectomy is a major risk factor for herniation recurrence. Carragee et al. [10] reported symptomatic herniation recurrence rates of 27% in defects larger than 6 mm, but only 1% in small annular fissures. Thus, the clinical burden of herniation recurrence after microdiscectomy may be mitigated by development of treatments that reliably occlude large annular defects. A bone-anchored annular closure device (ACD) has shown promising results in single-arm studies to address recurrent herniation after lumbar microdiscectomy [11,12]. The aim of this randomized controlled trial was to determine whether bone-anchored ACD, in addition to lumbar microdiscectomy, resulted in lower reherniation and reoperation rates plus increased overall success.

Methods

Trial design and oversight

We conducted a multicenter randomized controlled trial in patients who were operated on for sciatica caused by lumbar disc herniation and who had a large annular defect after lumbar discectomy. The primary objective of this trial was to determine whether implantation of a bone-anchored ACD after lumbar discectomy reduced the risk of recurrent herniation compared with lumbar discectomy alone. The clinical trial was approved by the local ethics committees, and all participants provided written informed consent. This study was prospectively registered at [ClinicalTrials.gov](https://clinicaltrials.gov) (NCT01283438). Details of the study rationale, design, and methods have been described previously [13].

The authors designed the trial in collaboration with the Food and Drug Administration. The study was sponsored

by Intrinsic Therapeutics, which manufactures the ACD and was involved in trial management and data monitoring. Two authors received study-specific support of more than \$10,000 per year, 8 authors received study-specific support less than \$10,000 per year, and 11 authors received no study-specific support. No authors, investigators, or site staff have any equity, royalty, or other financial interest in either Intrinsic Therapeutics or the Barricaid device. Data were analyzed by an independent statistician, and radiographic assessments were performed by an independent core laboratory blinded to patient outcomes. All authors had full access to the data and the data analysis.

Participants

At 21 European hospitals, we enrolled patients 21–75 years of age, with imaging confirmation of single-level disc herniation between L1 and S1, with disc height ≥ 5 mm, and who failed ≥ 6 weeks of nonsurgical treatment. Magnetic resonance imaging (MRI) with T1- and T2-weighted axial and sagittal images, low-dose, multiplanar computed tomography (CT), and flexion-extension x-rays were performed. All patients had lumbar radiculopathy with positive straight leg raise or femoral stretch test, and Oswestry Disability Index score (ODI) and visual analog scale (VAS) leg pain score of at least 40/100 on each. Patients with spondylolisthesis (Grade II or higher), previous surgery at the index level, or osteoporosis were excluded. Additional information on the inclusion and exclusion criteria are provided in [Supplementary Table S1](#).

Interventions

Experienced spinal surgeons had performed at least three cases with ACD implantation before enrolling patients in this study. With patients under general anesthesia in most cases, magnification-assisted limited discectomy was performed via an interlaminar transflaval approach [14]. After completion of the discectomy, the annular defect was measured with sizing probes provided in an accessory kit, and the final inclusion criterion was applied. If the annular defect was 4–6 mm tall and 6–10 mm wide, the patient qualified for randomization and no additional disc material was removed. This range of annular defect sizes was chosen to identify patients at high risk of recurrence that could also be treated within the range of available device sizes. In patients allocated to the control group, the procedure was concluded by standard incision closure. Patients allocated to ACD received bone-anchored annular closure under fluoroscopic guidance. The ACD is composed of a flexible polymer mesh to close the annular defect and a titanium anchor to secure the mesh to an adjacent vertebral body ([Supplementary Fig. S1](#)). The titanium anchor does not interfere with MRI interpretation or

the ability to detect reherniation. Postoperative care was provided according to the protocols of the participating surgical departments.

Follow-up and outcomes

Patients returned for follow-up visits at 6 weeks, 3 months, 6 months, 1 year, and 2 years. Computed tomography, MRI, and flexion-extension x-rays were performed at 1 and 2 years ([Supplementary Table S2](#)). Outcomes of this trial were measured using patient-reported data obtained from questionnaires, independent imaging assessment, and investigator reports of adverse events and reoperations. Patient-reported outcomes included ODI for back-related disability (0–100 scale) [15], VAS (0–100 scale) for back and leg pain [16], and health-related quality of life with the Medical Outcomes Study 36-Item Short-Form General Health Survey (SF-36) scale [17].

The trial included two co-primary end points. Study success required that outcomes with ACD were statistically superior to controls for both end points. One primary end point was incidence of recurrent herniation through 2 years. Recurrent herniation was confirmed during reoperation or by identification of protrusion, extrusion, or sequestration at any location of the index-level disc on imaging by independent radiologists [18]. The other primary end point was a composite consisting of (1) ≥ 15 -point improvement in ODI compared with baseline; (2) ≥ 20 -point improvement in leg pain VAS compared with baseline; (3) maintenance of $\geq 75\%$ disc height compared with baseline; (4) maintenance of device condition and neurologic status; and (5) freedom from index level reherniation, index level reoperation, and spontaneous fusion. Given that each primary end point comprised imaging findings even if no clinical symptoms were present, a post hoc modified composite end point was developed that included only symptomatic outcomes and was considered more clinically meaningful. This modified composite end point consisted of (1) freedom from symptomatic recurrent herniation, (2) ≥ 15 -point improvement in ODI compared with baseline, (3) ≥ 20 -point improvement leg pain VAS compared with baseline, (4) maintenance of neurologic status, (5) freedom from device- or procedure-related serious adverse event, and (6) freedom from index level reoperation.

Symptomatic herniation recurrence included recurrent herniation that was either surgically verified during reoperation, identified by the imaging core laboratory where the patient reported at least moderate (40/100) disability, radicular symptoms, and neurologic deterioration, or reported as an adverse event. The decision to reoperate during follow-up was collectively made by one of the investigators and the patient based on imaging findings, patient-reported symptoms, and patient preferences. The occurrence of adverse events was ascertained at each study contact and routinely monitored for accuracy. An independent data safety monitoring board (DSMB) adjudicated adverse events

by seriousness and by relatedness to the procedure or implant.

Randomization and blinding

After lumbar discectomy and intraoperative confirmation of eligible defect measurements, patients were randomly allocated in a 1:1 ratio, with a block size of four, to receive additional ACD or discectomy alone. Simple randomization was performed intraoperatively with a central web-based system that enabled real-time computer-generated random treatment assignment. Neither surgeons nor patients were blinded to the treatment group except for patients in the Netherlands who were blinded to the treatment group because of regional allowances.

Statistical analysis

A Bayesian approach to sample size selection was used [19]. Interim analyses were performed after enrollment of 400 patients and repeated at increments of 50 patients thereafter until the predictive probability of trial success on each primary end point exceeded 90% or the maximum sample size of 800 patients was reached. Efficacy analyses were performed on a modified intention-to-treat (ITT) population, which included all randomized patients in whom the intended procedure was attempted. Safety analyses were performed on an as-treated population. An ITT (as randomized) population was included as a sensitivity analysis. Baseline patient characteristics are presented as means and standard deviations for continuous variables and numbers and percentages for categorical variables. Outcomes between the groups were assessed with Student *t* test for continuous data or Fisher exact test for categorical data. Time-to-event data were analyzed using Kaplan-Meier methods with log-rank tests for group comparisons. Statistical significance was set at $P < .05$ and hypothesis testing was two-sided. Statistical analyses were performed using SAS v9.4 (SAS Institute, Cary, NC, USA) and R v3.3.2 (R Foundation for Statistical Computing, Vienna, Austria).

Results

Between December 2010 and October 2014, 554 patients were randomly allocated to ACD ($n=276$) or control ($n=278$). A list of participating centers is reported in [Supplementary Table S3](#). In four patients allocated to ACD, implantation was not attempted owing to proximity of the nerve root to the planned implant location. Therefore, the modified ITT population included 550 patients (272 ACD, 278 controls). Implantation of the ACD was unsuccessful in five patients, including four patients in whom the mesh did not fully enter the disc and one patient with nerve root injury during attempted implantation; thus, the as-treated population included 267 patients in the ACD group and 283 controls. Compliance with clinical follow-up at 2 years was 91% in each group ([Fig. 1](#)).

Table 1
Baseline characteristics of the patients*

Characteristic	Annular closure (n=272)	Control (n=278)
Age—y	43±11	44±10
Male sex—no. (%)	156 (57)	171 (62)
Body mass index—kg/m ²	26±4	26±4
Smoking history—no. (%)	173 (64)	175 (63)
Medical history—no. (%) †		
Musculoskeletal	95 (35)‡	91 (33)§
Head and neck	62 (23)‡	54 (20)§
Gastrointestinal	53 (20)¶	59 (21)‡
Cardiovascular	49 (18)‡	48 (17)‡
Genitourinary	39 (14)‡	35 (13)‡
Skin	29 (11)‡	30 (11)‡
Respiratory	28 (10)‡	44 (16)‡
Visual analog scale for leg pain¶	81±15	81±15
Visual analog scale for back pain¶	57±30	56±31
Oswestry Disability Index score#	59±12	58±14
SF-36 Physical Component Summary score**	29±6	29±6
SF-36 Mental Component Summary score**	40±13	41±13
Index level—no. (%)		
L2-L3	2 (1)	1 (<1)
L3-L4	8 (3)	5 (2)
L4-L5	123 (45)	101 (36)
L5-S1	139 (51)	171 (62)
Spondylolisthesis, Grade 1	6 (2)	8 (3)
Disc height—mm	8.9±2.1	8.9±2.2
Extrusion/Sequestration—no. (%)	201 (74)	201 (72)

* Plus-minus values are mean±SD.

† Medical history variables reported with frequency of 10% or more in either group.

‡ Data from two patients not reported.

§ Data from one patient not reported.

¶ Data from three patients not reported.

¶ Scores on the visual analog scale (VAS) range from 0 to 100, with higher scores indicating more severe pain.

Scores on the Oswestry Disability Index (ODI) range from 0 to 100, with higher scores indicating more severe disability.

** Physical Component Summary and Mental Component Summary scores from the Medical Outcomes Study 36-Item Short-Form General Health Survey (SF-36) scale range from 0 to 100, with higher scores indicating better health-related quality of life.

Treatment groups were well matched at baseline (Table 1). The mean age of the study population was 43 years, and 59% were men, which is consistent with findings in previous reports of patients undergoing lumbar microdiscectomy [4,20]. The mean volume of nucleus removal was 1.3 mL in each group; surgery duration (70 minutes vs. 52 minutes, $P<.001$) and procedural blood loss (98 cc vs. 67 cc, $P<.01$) were higher with ACD versus controls.

Herniation recurrence, diagnosed based on imaging or symptoms, was identified in 50% of patients in the ACD group and in 70% of controls at 2 years (mean difference: -20% , 95% confidence interval [CI]: -12% to -28% , $P<.001$) (Table 2). Clinical success on the primary composite end point was 27% with ACD and 18% with controls (mean difference: 9%, 95% CI: 2%–16%, $P=.02$). Thus, both co-primary end points of the study were met. Outcomes of the modified composite end point yielded similar conclusions,

with 76% success in the ACD group and 66% in controls (mean difference: 10%, 95% CI: 2%–18%, $P<.02$) (Supplementary Table S4).

The frequency of symptomatic reherniation was lower with ACD (12% vs. 25%, $P<.001$) (Fig. 2). Mean leg pain severity decreased by 84%, on average, at the regular visits over 2 years with no difference between groups (Supplementary Fig. S2). Back pain severity decreased by 66%, on average, at the regular visits through 2 years with no difference between groups (Supplementary Fig. S3). At 2 years, mean ODI scores were comparable (Supplementary Fig. S4). Health-related quality of life significantly improved with no differences observed between groups. Physical component summary scores increased from 29±6 to 49±9 with ACD and 29±6 to 47±9 in controls (Supplementary Fig. S5). Mental component summary scores increased from 40±13 to 52±10 with ACD and 41±13 to 51±11 in controls (Supplementary Fig. S6).

Index level reoperations were less frequent with ACD (9% vs. 16%, $P=.01$). There were 29 reoperations in 24 ACD patients and 61 reoperations in 45 control patients (Fig. 3). The frequency of index level reoperations specifically to address an observed recurrent herniation was 5% with ACD (14 procedures in 14 subjects) and 13% in controls (42 procedures in 37 subjects) ($P<.001$). Of the 14 reoperations for recurrence in the ACD group, 3 were also associated with detachment of the mesh portion of the device from the anchor and the fourth one was associated with a fracture of anchor head; in each of these cases, the detached portion was removed and the rest remained implanted. In the as-treated population, the frequency of serious adverse events adjudicated by the DSMB as related to either the implant or procedure was 7% in the ACD group and 17% in the control group ($P=.001$); this difference was primarily due to the lower incidence of reherniation in the ACD group. No difference in all-cause serious adverse events was observed when comparing ACD with controls (25% vs. 30%, $P=.15$). The frequency of adverse events, regardless of seriousness or relatedness, was 75% with ACD and 70% in controls ($P=.29$). Serious device- and procedure-related serious adverse events in the modified ITT population are reported in Table 3. Detailed listings of serious adverse events, serious device- and procedure-related adverse events, and adverse events regardless of seriousness or relatedness are reported in Supplementary Tables S5–S7 for the as-treated population and Supplementary Tables S8–S9 for the modified ITT population.

Assessment of all available CT images by the independent radiographic core laboratory identified end plate changes (disruptions in the smooth cortical margin of the bony end plate) after surgery with and without the ACD. Changes were more prevalent in the ACD group at 2 years (84% vs. 30%, $P<.001$), although no correlation with any symptom or clinically adverse event was observed.

A sensitivity analysis of main study outcomes in an ITT population did not alter study conclusions (Supplementary Table S10).




Fig. 1. Enrollment and randomization of patients. Intent-to-treat (ITT) population consisted of 276 patients assigned to annular closure device (ACD) group and 278 patients assigned to control group. Modified ITT population consisted of 272 patients with attempted ACD implant and 278 patients assigned to control group. As-treated population consisted of modified ITT population where 267 patients received ACD and 283 received control. In the as-treated population, failed ACD implantation in five ACD patients from the modified ITT population (including one with nerve root injury) resulted in assignment to the control group. Compliance with clinical follow-up at 2 years was 91% in each group.

Discussion

This multicenter randomized controlled trial demonstrated that additional use of a bone-anchored ACD after lumbar microdiscectomy reduced the risk of symptomatic recurrence and associated reoperations. The number needed to treat to prevent a reherniation was less than 8 and to prevent an associated reoperation was less than 13. Further, these benefits were not offset by a higher risk of adverse events. Given

that lumbar discectomy is the most frequently performed spine surgery in the United States with close to half a million procedures each year [9], the findings of this study have significant societal importance, as reoperations are known to be associated with poor outcome and extensive additional costs [6,8].

The results of this study are generalizable to patients with large annular defects after lumbar microdiscectomy.

Table 2
Main outcomes at 2 years*

Characteristic	Annular closure	Control	p-Value
Index level recurrent herniation—no. (%) [†]			
Symptomatic	31/250 (12)	65/257 (25)	<.001
Symptomatic and asymptomatic	125/250 (50)	180/257 (70)	<.001
Index level reoperation—no. (%) [‡]			
Recurrent herniation	14/272 (5)	37/278 (13)	.001
Any cause	24/272 (9)	45/278 (16)	.01
Neurologic function decline—no. (%) [§]	5/252 (2)	12/251 (5)	.09
Visual analog scale for leg pain	12±21 ^{**}	14±21 ^{**}	.32
Visual analog scale for back pain	18±23 ^{**}	19±24 ^{**}	.54
Oswestry Disability Index score	13±14 ^{**}	14±15 ^{**}	.27
SF-36 Physical Component Summary score ^{,**}	49±9 ^{**}	47±9 ^{**}	.07
SF-36 Mental Component Summary score ^{,**}	52±10 ^{**}	51±11 ^{**}	.23
Serious adverse event—no. (%) ^{††}			
Device- or procedure-related	19/267 (7) ^{§§}	47/283 (17)	.001
Any cause	66/267 (25)	86/283 (30)	.15

* Plus-minus values are mean±SD.

[†] Denominator includes patients in the modified intent-to-treat population with imaging at 2 years and patients with recurrent herniation at any time during follow-up.

[‡] Denominator includes all patients in the modified intent-to-treat population.

[§] Denominator includes all patients in the modified intent-to-treat population with data at baseline and 2 years.

^{||} Denominator includes all patients in the modified intent-to-treat population with data at 2 years.

^{||} Scores on the visual analog scale (VAS) range from 0 to 100, with higher scores indicating more severe pain.

[#] Scores on the Oswestry Disability Index (ODI) range from 0 to 100, with higher scores indicating more severe disability.

^{**} Physical Component Summary and Mental Component Summary scores from the Medical Outcomes Study 36-Item Short-Form General Health Survey (SF-36) scale range from 0 to 100, with higher scores indicating better health-related quality of life.

^{††} Denominator includes all patients in the as-treated population.

^{**} N=252.

^{§§} N=8 subjects experienced a device-related SAE.

Although the symptomatic recurrence rate of 25% in the control group was markedly higher than the 7%–18% recurrence rates frequently reported after discectomy [5–7], this was an anticipated result given the large annular defect inclusion criterion. McGirt et al. [7] reported that recurrence rates were four times higher in patients in the top quartile of

annular defect size versus those in the lower quartile. In patients with annular defect size ≥6 mm, recurrence rates through 2-year follow-up were 18% in the study of Kim et al. [21] and 27% in the study of Carragee et al. [10]. These findings have been corroborated in a meta-analysis that reported the risk of reherniation and reoperation after limited lumbar discectomy was approximately threefold higher in patients with large versus small annular defects [22].

The co-primary end points of the study must be interpreted within the context of a sample at high risk of recurrence, as well as considering that the threshold for defining recurrence was stringent. The definition of reherniation included imaging evidence of protrusion, extrusion, or sequestration, even in asymptomatic patients. Indeed, the majority of recurrent disc herniations were classified as protrusions in asymptomatic patients. Although both co-primary end points of the trial were met, each end point included information that was derived from imaging assessments. The clinical relevance of these end points is debatable given the known lack of association between MRI findings and symptoms in this population [23,24]. Given the inherent challenges with interpretation of the primary end points based on the asymptomatic reherniation rate of 42% in the entire sample, a post hoc modified composite end point was developed that was considered to be more clinically meaningful and demonstrated an increase of the success rate by 10% with ACD (76% vs. 66% in controls). Overall, additional ACD implantation reduced the risk of clinically important




Fig. 2. Freedom from symptomatic index level reherniation through 2 years. Kaplan-Meier freedom from event estimates in the modified intent-to-treat population through the end of the 2-year follow-up interval (Day 790) were 88.3% for annular closure device (ACD) and 75.6% for control (log-rank p-value<.001).




Fig. 3. Freedom from index level reoperation through 2 years. (Left) Kaplan-Meier freedom from index level reoperation for any reason estimates in the modified intent-to-treat population through the end of the 2-year follow-up interval (Day 790) were 91.0% for annular closure device (ACD) and 83.4% for control (log-rank p-value<.01). (Right) Kaplan-Meier freedom from index level reoperation for symptomatic reherniation estimates in the modified intent-to-treat population through the end of the 2-year follow-up interval (Day 790) were 94.7% for ACD and 86.2% for control (log-rank p-value<.001).

outcomes such as symptomatic herniation recurrence and reoperation, which are arguably the most important findings of this study.

Prevention of recurrent symptomatic herniation is a clinically meaningful pursuit as repeat discectomy is technically demanding and considerably more expensive compared with primary discectomy [25]. Several strategies to repair, replace, or regenerate the herniated nucleus pulposus have been evaluated yet none have resulted in a clinically proven therapy as the damaged annulus fibrosus had been largely

ignored [26,27]. The annulus fibrosus has limited regenerative capacity, which is likely because exterior repairs are not matched to the demands of intradiscal tensile forces [26]. Efforts to develop a definitive annular repair mechanism to date have been unsuccessful. The implant that was evaluated in the present study is anchored into the adjacent vertebral body, which may provide a more durable repair. On balance, some clinical considerations with the ACD include longer procedure time and potential for device-related problems. As previously demonstrated after ACD

Table 3
Serious device- and procedure-related adverse events through 2 years: modified intent-to-treat population

Event	Annular closure (n=272)			Control (n=278)			Significance	
	Events	Patients	%	Events	Patients	%	Diff	p-Value
Any serious device- or procedure-related adverse event	29	21	7.7%	56	45	16.2%	-8.5%	.002
Cardiac and vascular	0	0	0.0%	3	3	1.1%	-1.1%	.25
Bleeding	0	0	0.0%	1	1	0.4%	-0.4%	
Other	0	0	0.0%	2	2	0.7%	-0.7%	
Device deficiency	7	7	2.6%					
Device deficiency—anchor (whole device) migration	3	3	1.1%					
Device deficiency—mesh migration—extradiscal	4	4	1.5%					
Disc herniation	13	11	4.8%	43	38	15.5%	-10.7%	<.001
Herniation—index level	11	9	4.0%	43	38	15.5%	-11.4%	
Residual herniation—index level	2	2	0.7%	0	0	0.0%	0.7%	
Musculoskeletal—lumbar	1	1	0.4%	0	0	0.0%	0.4%	.50
Other	1	1	0.4%	0	0	0.0%	0.4%	
Neuro—lumbar and lower extremity	1	1	0.4%	0	0	0.0%	0.4%	.50
Nerve or spinal root injury: index surgery	1	1	0.4%	0	0	0.0%	0.4%	
Pain—lumbar and lower extremity	4	4	1.5%	2	2	0.7%	0.8%	.45
Lower extremity only	2	2	0.7%	2	2	0.7%	0.0%	
Lumbar	1	1	0.4%	0	0	0.0%	0.4%	
Lumbar and lower extremity	1	1	0.4%	0	0	0.0%	0.4%	
Wound issue—secondary surgical intervention at index level	3	3	1.1%	8	6	2.9%	-1.8%	.50
Dural injury/tear or cerebrospinal fluid leak	1	1	0.4%	1	1	0.4%	0.0%	
Infection	1	1	0.4%	3	2	1.1%	-0.7%	
Hematoma	0	0	0.0%	1	1	0.4%	-0.4%	
Delayed wound healing	1	1	0.4%	0	0	0.0%	0.4%	
Dehiscence	0	0	0.0%	1	1	0.4%	-0.4%	
Deep	0	0	0.0%	2	2	0.7%	-0.7%	

implantation, focal areas of bone resorption at the end plates were noted more frequently in the ACD group, but there was no relationship of these radiological findings with clinical parameters [26].

Our study had several strengths including effective randomization, high follow-up rates, a sample size representing one of the largest studies in spine surgery, oversight provided by a DSMB, and study design collaboration with the Food and Drug Administration. There are also several important limitations of this research. The results of this trial are not generalizable to all patients undergoing lumbar discectomy for disc herniation. Patients with inadequate disc height or small annular defects are not eligible for ACD implantation owing to surgical access challenges and likely would not benefit from preventative annular closure. Although patients in this study will be followed up for 5 years, long-term outcomes with ACD are currently unknown. Finally, the possible influence of expectation bias cannot be ruled out as most patients and all surgeons were aware of treatment assignment. However, when comparing patient outcomes from sites where the principal investigator reported a financial relationship with the study sponsor versus those with no such relationship, there were no differences in study conclusions. This finding held true for the primary end point, reherniation rates, reoperation rates, VAS scores, and ODI scores. Further, imaging studies were evaluated by independent radiologists.

Conclusion

In this randomized controlled trial of patients at high risk of herniation recurrence after lumbar microdiscectomy, additional annular closure with a bone-anchored device lowers the risk of recurrent herniation and reoperation through 2-year follow-up.

Acknowledgments

We thank Greg Maislin, PhD, of Biomedical Statistical Consulting for performing data analysis and Larry Miller, PhD, of Miller Scientific Consulting, Inc, for providing critical review and editorial assistance.

Supplementary material

Supplementary material related to this article can be found at <https://doi.org/10.1016/j.spinee.10.1016/j.spinee.2018.05.003>.

References

- [1] Frymoyer JW. Back pain and sciatica. *N Engl J Med* 1988;318:291–300.
- [2] Vroomen PC, de Krom MC, Knottnerus JA. Predicting the outcome of sciatica at short-term follow-up. *Br J Gen Pract* 2002;52:119–23.
- [3] Vroomen PC, de Krom MC, Wilmink JT, Kester AD, Knottnerus JA. Lack of effectiveness of bed rest for sciatica. *N Engl J Med* 1999;340:418–23.
- [4] Peul WC, van Houwelingen HC, van den Hout WB, Brand R, Eekhof JA, Tans JT, et al. Surgery versus prolonged conservative treatment for sciatica. *N Engl J Med* 2007;356:2245–56.
- [5] Carragee EJ, Spinnickie AO, Alamin TF, Paragioudakis S. A prospective controlled study of limited versus subtotal posterior discectomy: short-term outcomes in patients with herniated lumbar intervertebral discs and large posterior annular defect. *Spine* 2006;31:653–7.
- [6] Ambrossi GL, McGirt MJ, Sciubba DM, Witham TF, Wolinsky JP, Gokaslan ZL, et al. Recurrent lumbar disc herniation after single-level lumbar discectomy: incidence and health care cost analysis. *Neurosurgery* 2009;65:574–8. discussion 8.
- [7] McGirt MJ, Eustacchio S, Varga P, Vilendecic M, Trummer M, Gorenssek M, et al. A prospective cohort study of close interval computed tomography and magnetic resonance imaging after primary lumbar discectomy: factors associated with recurrent disc herniation and disc height loss. *Spine* 2009;34:2044–51.
- [8] Parker SL, Mendenhall SK, Godil SS, Sivasubramanian P, Cahill K, Ziewacz J, et al. Incidence of low back pain after lumbar discectomy for herniated disc and its effect on patient-reported outcomes. *Clin Orthop Relat Res* 2015;473:1988–99.
- [9] Gray DT, Deyo RA, Kreuter W, Mirza SK, Heagerty PJ, Comstock BA, et al. Population-based trends in volumes and rates of ambulatory lumbar spine surgery. *Spine* 2006;31:1957–63. discussion 64.
- [10] Carragee EJ, Han MY, Suen PW, Kim D. Clinical outcomes after lumbar discectomy for sciatica: the effects of fragment type and annular competence. *J Bone Joint Surg Am* 2003;85-A:102–8.
- [11] Bouma GJ, Barth M, Ledic D, Vilendecic M. The high-risk discectomy patient: prevention of reherniation in patients with large annular defects using an annular closure device. *Eur Spine J* 2013;22:1030–6.
- [12] Ledic D, Vukas D, Grahovac G, Barth M, Bouma GJ, Vilendecic M. Effect of annular closure on disk height maintenance and reoperated recurrent herniation following lumbar discectomy: two-year data. *J Neurol Surg A Cent Eur Neurosurg* 2015;76:211–18.
- [13] Klassen PD, Hes R, Bouma GJ, Eustacchio S, Barth M, Kursumovic A, et al. A multicenter, prospective, randomized study protocol to demonstrate the superiority of a bone-anchored prosthesis for annular closure used in conjunction with limited discectomy to limited discectomy alone for primary lumbar disc herniation. *Int J Clin Trials* 2016;3:120–31.
- [14] Spengler DM. Lumbar discectomy. Results with limited disc excision and selective foraminotomy. *Spine* 1982;7:604–7.
- [15] Stromqvist B, Fritzell P, Hagg O, Jonsson B, Swedish Society of Spinal Surgeons. The Swedish Spine Register: development, design and utility. *Eur Spine J* 2009;18(Suppl. 3):294–304.
- [16] Collins SL, Moore RA, McQuay HJ. The visual analogue pain intensity scale: what is moderate pain in millimetres? *Pain* 1997;72:95–7.
- [17] Brazier JE, Harper R, Jones NM, O’Cathain A, Thomas KJ, Usherwood T, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. *BMJ* 1992;305:160–4.
- [18] Jensen MC, Kelly AP, Brant-Zawadzki MN. MRI of degenerative disease of the lumbar spine. *Magn Reson Q* 1994;10:173–90.
- [19] Berry DA. Interim analyses in clinical trials: classical vs. Bayesian approaches. *Stat Med* 1985;4:521–6.
- [20] Lequin MB, Verbaan D, Jacobs WC, Brand R, Bouma GJ, Vandertop WP, et al. Surgery versus prolonged conservative treatment for sciatica: 5-year results of a randomised controlled trial. *BMJ Open* 2013;3.
- [21] Kim KT, Lee DH, Cho DC, Sung JK, Kim YB. Preoperative risk factors for recurrent lumbar disk herniation in L5-S1. *J Spinal Disord Tech* 2015;28:E571–7.
- [22] Miller LE, McGirt MJ, Garfin SR, Bono CM. Association of annular defect width following lumbar discectomy with risk of symptom recurrence and reoperation: systematic review and meta-analysis of comparative studies. *Spine* 2017.

- [23] Boos N, Rieder R, Schade V, Spratt KF, Semmer N, Aebi M. 1995 Volvo Award in clinical sciences. The diagnostic accuracy of magnetic resonance imaging, work perception, and psychosocial factors in identifying symptomatic disc herniations. *Spine* 1995;20:2613–25.
- [24] Jensen MC, Brant-Zawadzki MN, Obuchowski N, Modic MT, Malkasian D, Ross JS. Magnetic resonance imaging of the lumbar spine in people without back pain. *N Engl J Med* 1994;331:69–73.
- [25] Sherman J, Cauthen J, Schoenberg D, Burns M, Reaven NL, Griffith SL. Economic impact of improving outcomes of lumbar discectomy. *Spine J* 2010;10:108–16.
- [26] Bron JL, Helder MN, Meisel HJ, Van Royen BJ, Smit TH. Repair, regenerative and supportive therapies of the annulus fibrosus: achievements and challenges. *Eur Spine J* 2009;18:301–13.
- [27] Guterl CC, See EY, Blanquer SB, Pandit A, Ferguson SJ, Benneker LM, et al. Challenges and strategies in the repair of ruptured annulus fibrosus. *Eur Cell Mater* 2013;25:1–21.